Trial Profile
A Phase I Dose-Escalation Study of OSI-906 and Erlotinib (Tarceva) in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Linsitinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 01 Feb 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 21 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Apr 2011 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.